At Memorial Sloan Kettering Cancer Center, our world-renowned scientists are constantly advancing our knowledge about cancer, and our discoveries are improving care for patients here and all over the world. On this page, you will find information about our groundbreaking work and the dedicated professionals who make it all happen.

For Journalists

Connect with us to reach MSK experts for media inquiries and for story ideas.

Learn more

Press Releases
Shelly Anderson, MPM
Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.
Deb Schrag
Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer.
View all press releases
Kieran Healy is seen smiling outdoors next to his bike, after successful treatment for lymphoma at Memorial Sloan Kettering.
Kieran Healy was feeling worse by the day. A new father at 43 years old, he was bone-tired and losing weight. He had night sweats and a strange lump in his belly. His local hospital in Manhattan ordered an ultrasound and a CT (computed tomography) scan — but they were scheduled over a month away.
Michael Berger, PhD, Co-Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and Elizabeth and Felix Rohatyn Chair for Junior Faculty
MSK has developed an arsenal of tests that are at the front lines of precision treatments. They target the structure of proteins that cause cancer, offering people new hope.
View all articles
2022 Annual Report: It Takes MSK
Shanu Modi, MD, expert in developing new breast cancer treatments
MSK-led research could change the practice of medicine for millions of people whose breast cancer has spread. Research led by Dr. Shanu Modi has demonstrated that a targeted drug called trastuzumab deruxtecan blocks the protein HER2 even when its levels are low — the case for about 55% of people with breast cancer.
Scott Lowe, PhD, identified a precancerous sign in cells that is “sort of like the first wobble as the wheels start to fall off the wagon.”
The protein made by the p53 gene helps guard the body against cancer, in part by detecting and repairing damaged DNA. Over the 30 years since p53 was first discovered, it has remained a stubborn mystery, resisting efforts to tease apart exactly how the loss of the gene’s protection leads to the development of cancer. In August 2022, researchers in the Sloan Kettering Institute were able to provide some new answers that hint at new avenues for treatment.
View the full report
Cancer Straight Talk
Cancer Straight Talk brings together national experts and cancer patients to have straightforward, evidence-based conversations. Medical oncologist Diane Reidy-Lagunes hosts this series with the mission of educating and empowering patients to make the right decisions and live happier, healthier lives.